Other
Graft Rejection
0
Pipeline Programs↗
1
Active Trials↗
2
Companies Involved↗
Graft Rejection is an early-stage landscape with 0 programs across 2 companies. The most active players are Neovii Biotech, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
10
clinical trials
Completed6 · 60%
Unknown status3 · 30%
Recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
Impact of the Microbiota on the Likelihood of Renal Graft Rejection
Recruiting·IInstitut National de la Santé Et de la Recherche Médicale, France·N/A·NCT04736381·70 enrolled
Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
Completed·—·Phase 3·NCT00147381·197 enrolled
Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection
Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT05913583·160 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)